Leaflet BRIVAL 125mg tablets


Indicated for: herpes zoster

Substance: brivudine (antiviral)

ATC: J05AB15 (Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors)

Brivudinum is an antiviral medication used for the treatment of varicella-zoster virus (VZV) infections, particularly in patients with shingles. It works by inhibiting viral replication, reducing the severity and duration of symptoms.

The medication is taken orally, usually once daily, as directed by a doctor. Treatment should be started as soon as possible after symptom onset to be effective.

Common side effects include nausea, headache, and fatigue. In rare cases, allergic reactions or liver function impairment may occur, requiring close monitoring of patients.

Brivudinum is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions.

General data about BRIVAL 125mg

  • Substance: brivudine
  • Date of last drug list: 01-05-2026
  • Commercial code: W12651002
  • Concentration: 125mg
  • Pharmaceutical form: tablets
  • Quantity: 7
  • Product type: original
  • Price: 247.92 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: BERLIN CHEMIE AG MENARINI GROUP - GERMANIA
  • Holder: BERLIN CHEMIE AG MENARINI GROUP - GERMANIA
  • Number: 900/2008/01
  • Shelf life: 3 years

Compensation lists for BRIVAL 125mg Berlin Chemie

B - Sublist B with 50% discount from the reference price

Price

Copayment

Patient

247.92 RON

123.96 RON

123.96 RON

NHP 1.A (C2) - People with HIV/AIDS and post-exposure treatment

Price

Copayment

Patient

247.92 RON

247.92 RON

0.00 RON